These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38831012)

  • 21. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.
    Cui T; Hurtig M; Elgue G; Li SC; Veronesi G; Essaghir A; Demoulin JB; Pelosi G; Alimohammadi M; Öberg K; Giandomenico V
    PLoS One; 2010 Dec; 5(12):e16010. PubMed ID: 21209860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours?
    Numbere N; Huber AR; Shi C; Cates JMM; Gonzalez RS
    Histopathology; 2019 Feb; 74(3):424-429. PubMed ID: 30326145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations of Tobacco and Alcohol Use with Risk of Neuroendocrine Tumors of the Small Intestine in Utah.
    Curtin K; Cannon-Albright LA; VanDerslice J; Yu Z; Herget KA; Thota R; Neklason DW
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):1998-2004. PubMed ID: 31558509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting the risk of emergency admission with machine learning: Development and validation using linked electronic health records.
    Rahimian F; Salimi-Khorshidi G; Payberah AH; Tran J; Ayala Solares R; Raimondi F; Nazarzadeh M; Canoy D; Rahimi K
    PLoS Med; 2018 Nov; 15(11):e1002695. PubMed ID: 30458006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
    Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
    Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
    Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
    Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.
    Liao W; Coupland CAC; Burchardt J; Baldwin DR; ; Gleeson FV; Hippisley-Cox J
    Lancet Respir Med; 2023 Aug; 11(8):685-697. PubMed ID: 37030308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival.
    Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M
    Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical signs of fibrosis in small intestinal neuroendocrine tumours.
    Daskalakis K; Karakatsanis A; Stålberg P; Norlén O; Hellman P
    Br J Surg; 2017 Jan; 104(1):69-75. PubMed ID: 27861745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs.
    Chen L; Zhou L; Zhang M; Shang L; Zhang P; Wang W; Fang C; Li J; Xu T; Tan H; Zhang P; Qiu M; Yu X; Jin K; Chen Y; Chen H; Lin R; Zhang Q; Shen L; Chen M; Li J; Li L; Chen J
    BMC Cancer; 2017 Aug; 17(1):521. PubMed ID: 28778195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary small intestinal neuroendocrine tumors are highly prevalent and often multiple before metastatic disease develops.
    Eriksson J; Norlén O; Ögren M; Garmo H; Ihre-Lundgren C; Hellman P
    Scand J Surg; 2021 Mar; 110(1):44-50. PubMed ID: 31587594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Clinical Prognostic Factors and Further Delineation of the Effect of Mesenteric Fibrosis on Survival in Advanced Midgut Neuroendocrine Tumours.
    Laskaratos FM; Walker M; Wilkins D; Tuck A; Ramakrishnan S; Phillips E; Gertner J; Megapanou M; Papantoniou D; Shah R; Banks J; Vlachou E; Garcia-Hernandez J; Woodbridge L; Papadopoulou A; Grant L; Theocharidou E; Watkins J; Luong TV; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2018; 107(3):292-304. PubMed ID: 30153671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors.
    Kim MK; Warner RR; Ward SC; Harpaz N; Roayaie S; Schwartz ME; Itzkowitz S; Wisnivesky J
    Neuroendocrinology; 2015; 101(1):58-65. PubMed ID: 25572143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for a heritable contribution to neuroendocrine tumors of the small intestine.
    Neklason DW; VanDerslice J; Curtin K; Cannon-Albright LA
    Endocr Relat Cancer; 2016 Feb; 23(2):93-100. PubMed ID: 26604321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum.
    Blažević A; Hofland J; Hofland LJ; Feelders RA; de Herder WW
    Endocr Relat Cancer; 2018 Mar; 25(3):R115-R130. PubMed ID: 29233841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours.
    Samsom KG; Levy S; van Veenendaal LM; Roepman P; Kodach LL; Steeghs N; Valk GD; Wouter Dercksen M; Kuhlmann KFD; Verbeek WHM; Meijer GA; Tesselaar MET; van den Berg JG
    Histopathology; 2021 Mar; 78(4):556-566. PubMed ID: 32931025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
    Wu Z; Shang G; Zhang K; Wang W; Fan M; Lin R
    Int J Surg; 2024 Apr; 110(4):2178-2186. PubMed ID: 38241384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
    Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
    World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors.
    Jahn U; Ilan E; Sandström M; Garske-Román U; Lubberink M; Sundin A
    Neuroendocrinology; 2020; 110(7-8):662-670. PubMed ID: 31597134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.